ARTICLE | Company News
Biotest, Abbott deal
June 27, 2011 7:00 AM UTC
Biotest granted Abbott exclusive, worldwide rights to develop and commercialize BT-061, a humanized mAb against CD4 in Phase II testing for rheumatoid arthritis (RA) and psoriasis. Biotest, which ret...